TickerFacts.

Company research / ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Build a valuation ↗↓ Download CSV

SEC name ALNYLAM PHARMACEUTICALS, INC. · CIK 0001178670 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B. Revenue grew 65.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $4.80B.

Key ratios (year ended 2025-12-31)

81.8%
Gross margin (computed)
13.5%
Operating margin
8.4%
Net margin
39.8%
Return on year-end equity
65.2%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-06

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.80B$3.71B$2.25B$1.83B$1.04B$844.29M$492.85M$219.75M$74.91M$89.91M$47.16M
Cost of Revenue$970.74M$677.17M$306.51M$268.22M$140.17M$115.00M$74.19M$25.06M$1.80M$0n/a
Gross Profit (computed)$3.83B$3.04B$1.94B$1.56B$897.24M$729.28M$418.67M$194.69Mn/an/an/a
R&D Expense$1.51B$1.32B$1.13B$1.00B$883.01M$792.16M$654.82M$655.11M$505.42M$390.63M$382.39M
Operating Income$999.78M$501.58M-$176.88M-$282.18M-$785.07M-$708.65M-$828.44M-$939.43M-$814.67M-$500.09M-$424.59M
Depreciation & Amortization$54.76M$55.66M$56.67M$54.05M$44.47M$47.57M$34.77M$17.18M$15.25M$11.90M$15.13M
EBITDA$1.05B$557.24M-$120.22M-$228.12M-$740.60M-$661.09M-$793.67M-$922.26M-$799.42M-$488.19M-$409.46M
Net Income$774.71M$313.75M-$278.16M-$440.24M-$1.13B-$852.82M-$858.28M-$886.12M-$761.50M-$490.87M-$410.11M
EPS (Diluted)n/a$2.33-$2.18-$3.52-$9.30-$7.20-$7.46-$8.11n/an/an/a
Total Assets$5.56B$4.97B$4.24B$3.83B$3.55B$3.64B$3.41B$2.40B$1.57B$1.99B$1.26B
Total Liabilities$4.20B$4.18B$4.17B$4.05B$3.70B$3.06B$2.39B$956.44M$272.84M$228.30M$342.59M
Shareholders' Equity$1.35B$789.18M$67.09M-$220.64M-$158.22M$588.20M$1.02B$1.44B$1.30B$1.77B$920.22M
Cash & Equivalents$1.71B$1.66B$966.43M$812.69M$866.39M$819.98M$496.58M$547.18M$420.15M$645.36M$193.62M
Operating Cash Flown/a$524.08M-$8.31M$104.16M-$541.27M-$641.69M-$614.96M-$278.43M-$562.62M-$382.79M-$307.70M
Capital Expenditures$91.95M$58.70M$34.28M$62.21M$72.06M$76.37M$70.36M$140.16M$126.89M$104.21M$64.56M
Free Cash Flown/a$465.38M-$42.59M$41.95M-$613.33M-$718.07M-$685.32M-$418.58M-$689.50M-$487.00M-$372.26M
Shares Outstanding133.73M132.38M129.29M125.79M123.92M120.18M116.43M112.19M101.18M99.67M85.94M
Weighted Average Diluted Sharesn/a134.68M127.65M124.91M121.69M118.45M114.99M109.26Mn/an/an/a
EPS (Basic)n/a$2.39-$2.18-$3.52-$9.30-$7.20-$7.46-$8.11n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView